Replies to post #13182 on Oncolix Inc. (fka ONCX)

[zen222]

Easy, there is a huge potential based on the science behind Prolanta.

126,000,000 shares will not be added to the float all at once. It doesn't take a stock guru to understand that won't happen.


Upcoming catalysts include:

Uplisting to OTCQB immediately after new ticker.

Major IR/PR push after ticket change/uplist

The company has identified 2 other drugs that they are looking to acquire.

Adding more prestigious board members and a world-class scientific advisory board.

MD Anderson will soon evaluate Prolanta for the treatment of endometrial cancer.

The company is currently pursuing a licensing partner for Prolanta in Asia.

Planning for Nasdaq uplist next year.

Again, please contact the management. We're not here to hold hands and babysit. [e-mail]